• Biotronik (Lake Oswego, Oregon) said that the recruitment phase of the Lumos-T Safely Reduces Routine Office Device Follow Up (TRUST) study has been completed early. TRUST is a randomized, multicenter trial of patients with implantable cardioverter defibrillators (ICD) using Biotronik Lumos and Lumax devices. The TRUST study will evaluate the effectiveness of using Home Monitoring technology to follow-up patients compared to periodic in-office follow-up. Home Monitoring is an innovation in cardiac device technology that Biotronik says it has pioneered. It allows patients to be monitored continuously and wirelessly by their physician from anywhere in the world and from any computer with an Internet connection. Unlike other systems which require cardiac device patients to activate remote monitoring (sometimes using complicated technology), Home Monitoring is automatic, mobile and requires no patient intervention, according to Biotronik.

• Cambridge Research & Instrumentation (CRI; Woburn, Massachusetts) said it is shipping DyCE (dynamic contrast enhancement), a new technology application, to users of the Maestro in vivo molecular imaging system. Customers can now generate all-optical anatomical images of mouse models in a few minutes, saving time and enabling better time-resolved images of molecular probe distribution. Anatomical images are produced using DyCE in the following way. A bolus of an inert near-infrared dye (such as indocyanine green) is injected, and then a time-based series of data is collected. Using CRI's analysis software, this data set is interpreted to delineate most of the major organ systems, using optical imaging alone. CRI is a manufacturer of optical imaging products.

• Masimo (Irvine, California) reported that a new clinical study, recently published in the Journal of Emergency Medicine, found the Masimo Rainbow SET Rad-57 Pulse CO-Oximeter to be"a safe, easily applied tool at triage that can identify cases of unsuspected elevated levels of carbon monoxide (CO) poisoning" otherwise undetected. The research team noted that identification of CO toxicity in the ED is challenging because many patients may not know or suspect that they were exposed to CO and are unable to provide clinicians with sufficient history to prompt testing for carboxyhemoglobin (COHb). Missing the opportunity to diagnose CO poisoning at the ED because screening large populations of patients by invasive blood testing for CO toxicity is not practical and not routinely performed in the ED setting can lead to"inadvertently returning a patient to the site of CO exposure and may lead to further toxicity with the possibility of long-term neurological, psychiatric, or cardiovascular complications." Masimo is the inventor of Pulse CO-Oximetry and Measure-Through-Motion & Low Perfusion Pulse Oximetry.